Cannatrek signs MoU to advance medicinal cannabis research
Cannatrek, an Australian vertically integrated plant-based medicine company, has signed a memorandum of understanding (MoU) with Mie University in Tsu, Japan, to forge an open collaboration focused on accelerating medical research into the use of cannabis. The strategic partnership marks the first-ever MoU for medicinal cannabis research between any Australian and Japanese organisation or government.
The MoU swiftly follows the Japanese Government’s recent change in stance towards the use of cannabis with the Lower House passing the bill to legalise the use of medical products made from cannabis in mid-November.
Cannatrek CEO Tommy Huppert said, “Cannatrek has the manufacturing capability to supply the highest quality of medicinal cannabis products for domestic and international markets via our Shepparton facility. The facility recently received Good Manufacturing Practice (GMP) accreditation, which further enhances export opportunities.”
Under the MoU, the framework for cooperation encompasses several key areas including agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance, and connecting experts in the field.
New GDM diagnosis recommendations welcomed
Australia's peak diabetes organisations have welcomed the publication of new recommendations...
Regulators step in as medicinal cannabis prescriptions soar
Concerned by reports of patients presenting to EDs with medicinal cannabis-induced psychosis,...
Diagnostic reference levels for mammography now a step closer
Australia is a step closer to diagnostic reference levels for mammography with the publication of...
